Every year, nearly 300 million people in China, including over 50 million cough patients, get infected with respiratory diseases. It is estimated that the number of asthma patients in China has exceeded 20 million. Inhaled corticosteroids are suitable for the long-term treatment of bronchial asthma and can avoid all kinds of adverse reactions caused by systemic use of corticosteroids. At present, the main inhaled corticosteroids used in clinical practice are Budesonide, Fluticasone and Beclomethasone.
In the 1990s, Budesonide was successfully developed by AstraZeneca to be used for the treatment of non-corticosteroid dependent or corticosteroid-dependent bronchial asthma and chronic obstructive pulmonary disease. In Jun. 1997, Budesonide aerosol was approved by the FDA.
In 1994, China approved the import of Budesonide. In 1995, Astra (Wuxi) Pharmaceutical was approved to manufacture and sell Budesonide in China. Budesonide has been developing rapidly since it entered the Chinese market. Its annual sales increased from approximately CNY 100 million in 2007 to approximately CNY 1.2 billion in 2017 with the CAGR from 2007 to 2017 up to 27.7%. There is a high demand for Budesonide in China. The majority of Budesonide currently sold on the market are manufactured by AstraZeneca, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical Co., Ltd., Orion Pharma and Shanghai Sine Pharmaceutical Laboratories Co., Ltd. In terms of sales, AstraZeneca has the highest market share, accounting for more than 90% of the Chinese market in 2017.
Owing to the aggravating environmental pollution and ageing population, China will see a rising incidence of respiratory diseases from 2018 to 2012, which will lead to an ever-expanding Budesonide market.
- Development history of Budesonide in China
- Size of Chinese Budesonide market
- Market share of major Budesonide manufacturers in China
- Market share of various dosage forms of Budesonide in China
- Budesonide prices on the Chinese market
- Prospects of Chinese Budesonide Market, 2018-2022
1 Relevant Concepts of Budesonide
1.1 Indications of Budesonide
1.2 Development History of Budesonide in China
1.3 Patent Status and Approval Information of Budesonide in China
2 Sales of Budesonide in China, 2013-2017
2.1 Sales Value of Budesonide
2.1.1 Sales Value of Budesonide in China
2.1.2 Sales Value by Region
2.2 Sales Volume of Budesonide
2.2.1 Sales Volume of Budesonide in China
2.2.2 Sales Volume by Regions
2.3 Sales of Various Dosage Forms of Budesonide in China,2013-2017
2.3.3 (Powder) Aerosols
3 Analysis on Major Budesonide Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Budesonide Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2.1 Enterprise Profile
3.2.2 Sales of AstraZeneca's Budesonide in China
3.3 Synmosa Biopharma Corporation
3.4 Lunan Better Pharmaceutical Co., Ltd.
3.5 Orion Pharma
3.6 Shanghai Sine Pharmaceutical Laboratories Co., Ltd.
4 Several Manufacturers’ Budesonide Prices on the Chinese Market, 2017-2018
4.2 Synmosa Biopharma Corporation
4.3 Lunan Better Pharmaceutical Co., Ltd.
4.4 Orion Pharma
4.5 Shanghai Sine Pharmaceutical Laboratories Co., Ltd.
5 Prospects of Chinese Budesonide Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend
Chart Patent Status of Budesonide in China
Chart Governmental Approval of Budesonide in China
Chart Sales of Budesonide in China
Chart Sales Value of Budesonide in China, 2013- 2017
Chart Sales Value of Budesonide in Parts of China, 2013-2017
Chart Sales Volume of Budesonide in China, 2013- 2017
Chart Market Share of Top 5 Budesonide Manufacturers in Sales Value, 2013-2017
Chart Market Share and Sales Value of AstraZeneca's Budesonide in China, 2013-2017
Chart Market Share and Sales Value of Synmosa's Budesonide in China, 2013-2017
Chart Market Share and Sales Value of Lunan Better's Budesonide in China, 2013-2017
Chart Sales Value and Market Share of Budesonide Suspensions in China, 2013-2017
Chart Sales Value and Market Share of Budesonide Sprays in China, 2013-2017
Chart Prices of AstraZeneca's Budesonide in Several Chinese Cities, 2017-2018
Chart Prices of SYNMOSA's Budesonide in Several Chinese Cities, 2017-2018
Chart Prices of Lunan Better's Budesonide in Several Chinese Cities, 2017-2018
Chart Forecast on Sales Value of Budesonide in China, 2018-2012
- Analysis on Market Share of Major Budesonide Manufacturers
- Synmosa Biopharma Corporation
- Lunan Better Pharmaceutical Co., Ltd.
- Orion Pharma
- Shanghai Sine Pharmaceutical Laboratories Co., Ltd.
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.